Class / Patent application number | Description | Number of patent applications / Date published |
514426000 | Nitrogen bonded directly to the five-membered hetero ring by nonionic bonding | 13 |
20080221201 | ARYL SULFONAMIDES USEFUL FOR MODULATION OF THE PROGESTERONE RECEPTOR - In one embodiment, compounds of the following structure are described, wherein R | 09-11-2008 |
20080287523 | Pyrrolidin-3-Yl Compounds Useful as Beta-Secretase Inhibitors for the Treatment of Alzheimer's Disease - The present invention is directed to pyrrolidin-3-yl derivative compounds which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved. | 11-20-2008 |
20090062373 | DEUTERIUM-ENRICHED PF-184298 - The present application describes deuterium-enriched PF-184298, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 03-05-2009 |
20090118353 | Medicinal composition - The present invention relates to an ameliorant for improving the movement of the digestive tract comprising, as an active ingredient, 4-amino-5-chloro-2-methoxy-N-[(2S,4S)-2-hydroxymethyl-4-pyrrolidinyl]benzamide or an acid addition salt thereof which is a metabolite of 4-amino-5-chloro-2-methoxy-N-[(2S,4S)-1-ethyl-2-hydroxymethyl-4-pyrrolidinyl]benzamide or an acid addition salt thereof, having high biding affinity for a serotonin receptor 4 (5HT | 05-07-2009 |
20090239928 | N-Pyrrolidin-3YL-Amide Derivatives As Serotonin and Noradrenalin Re-Uptake Inhibitors - A compound of Formula (I) and pharmaceutically and/or veterinarily acceptable derivatives thereof, wherein: R | 09-24-2009 |
20090239929 | N-Pyrrolidin-3-YL-Amide Derivatives As Serotonin and Noradrenalin Re-Uptake Inhibitors - A compound of Formula (I) and pharmaceutically and/or veterinarily acceptable derivatives thereof, wherein: R | 09-24-2009 |
20090264498 | Cathepsin C Inhibitors - This invention relates to compounds of formula (I) | 10-22-2009 |
20090264499 | Cathepsin C Inhibitors - A compound of formula (IA) or (IB) | 10-22-2009 |
20120142752 | HIV PROTEASE INHIBITORS - Compounds of Formula (I) are disclosed; wherein X | 06-07-2012 |
20120184594 | PHENYLPYRROLIDINE COMPOUNDS - This invention provides new phenylpyrrolidine compounds, their use for the treatment or prevention of melatoninergic disorders and its compositions. | 07-19-2012 |
20120238615 | Alpha adrenergic receptor modulators - Compounds are described herein useful for treating diseases and conditions by modulation of one or more alpha adrenergic receptor, in particular the alpha 2C receptor. The compounds can include N-(2,3-substituted phenyl)-3,4-dihydro-2H-pyrrol-5-amine derivatives. Methods of making, using and formulating these compounds are described | 09-20-2012 |
20160108012 | PROSTAGLANDIN CONJUGATES AND DERIVATIVES FOR TREATING GLAUCOMA AND OCULAR HYPERTENSION - Prostaglandin conjugates and derivatives and methods for their use to treat glaucoma and/or lower intraocular pressure are disclosed. Additionally, ophthalmic pharmaceutical compositions useful in the treatment of eye diseases such as glaucoma and elevated intraocular pressure are disclosed. Such compositions comprise an effective amount of prostaglandin conjugates or derivatives of the present invention. | 04-21-2016 |
20160200679 | NOVEL CRYSTALLINE ARYLALKYLAMINE COMPOUND AND PROCESS FOR PRODUCING THE SAME | 07-14-2016 |